Inspira Technologies Oxy B.H.N. Ltd. reports developments in Additively Manufactured Electronics, quantum connectivity and its medical technology portfolio. Company updates focus on AME system orders and deployments, QTREX-branded cryogenic interconnect work for superconducting quantum systems, customer activity with research, defense and technology organizations, and leadership or strategic-direction announcements.
The company's medical technology context includes respiratory support and blood monitoring platforms, including INSPIRA ART, INSPIRA ART100 and the HYLA Blood Sensor, while recent communications emphasize a dedicated medical business unit alongside the AME and quantum connectivity strategy.
Inspira (Nasdaq: IINN) announced on April 13, 2026 the start of an AME technology implementation with a customer described as one of the world's 10 largest U.S.-based companies. The rollout is already underway at a U.S. R&D facility and targets cryogenic connectivity for quantum computing using Inspira's acquired AME platform.
The company says this engagement validates the AME platform, reflects ongoing commercial activity with a top-tier technology customer, and supports recurring revenue prospects and broader demand from elite technology organizations.
Inspira (Nasdaq: IINN) is entering the quantum computing sector by directing its newly acquired additive manufactured electronics (AME) platform toward a 3D connectivity architecture for dilution cryostats. The company says the AME platform, developed with more than $200 million invested, has demonstrated proof of concept for qubit-related device integration.
Inspira intends to change its corporate name to QTREX Ltd. pending shareholder approval and is exploring collaborations while maintaining separate commercialization efforts for its medical products.
Inspira (Nasdaq: IINN) announced acquisition of Nano Dimension’s AME platform, acquiring intellectual property, high-precision 3D electronic printing systems, software, engineering know-how, equipment, inventory, customer-related assets and fully equipped facilities.
Total consideration is up to $12.5 million: a $2.0 million upfront cash payment and up to $10.5 million deferred payments tied to platform performance over the next 12 months; closing remains subject to customary regulatory approvals. Inspira assumed control effective immediately and will provide a further strategic update shortly.
Inspira Technologies (Nasdaq: IINN) has terminated its February 17, 2026 sales agreement with A.G.P./Alliance Global Partners and its December 12, 2025 Standby Equity Purchase Agreement with YA II PN, Ltd.
The company delivered formal written notices and stated there are no outstanding obligations or further advances under either agreement, citing a disciplined capital structure as it prepares for its next strategic phase.
Inspira (Nasdaq: IINN) reported full-year 2025 results and business updates on March 26, 2026, highlighting clinical validation and early commercial traction for the INSPIRA ART100 system.
Key points: $289k 2025 revenue from initial deployments, $49.5M binding purchase orders secured in mid-2025 expected to convert to 2026 revenue, R&D $7.496M, operating loss $13.22M, cash $3.159M at year-end, and a subsequent $4.75M registered direct offering boosting liquidity.
Inspira (NASDAQ: IINN, IINNW) received a Nasdaq notice dated Feb 19, 2026, that it is not in compliance with Listing Rule 5550(b)(2) requiring a minimum market value of publicly held shares of $35,000,000.
The company has a 180-day cure period through Aug 18, 2026, to regain compliance by closing at or above $35,000,000 for 10 consecutive business days; trading of ordinary shares continues on Nasdaq.
Inspira Technologies (NASDAQ: IINN, IINNW) deployed its FDA-cleared ART100 system at a leading New York academic medical center ranked in the state top 10. The system was integrated into clinical workflow to begin a structured commercial evaluation aimed at defining protocols and wider institutional adoption.
This deployment expands Inspira's presence in Tier-1 U.S. hospitals and supports the company's ongoing U.S. commercial strategy and evaluations at other major healthcare facilities.
Inspira Technologies (NASDAQ: IINN) will showcase its FDA-cleared ART100 at AmSECT 64th International Conference, March 25–29, 2026, in Austin, Texas, via U.S. distributor Glo-Med Networks.
The company is targeting perfusionists and cardiac surgical teams to accelerate U.S. commercial adoption, leveraging its FDA 510(k) clearance (May 2024) and active distribution channel for clinical integration.
Inspira Technologies (NASDAQ: IINN) received a Nasdaq written notification on Feb 9, 2026, for failing to meet the $1.00 minimum bid price under Nasdaq Listing Rule 5550(a)(2).
The company has a 180-calendar-day compliance period until Aug 10, 2026, to regain compliance by achieving a $1.00 closing bid for ten consecutive business days; shares continue to trade on Nasdaq during this period.
Inspira Technologies (NASDAQ: IINN) secured vendor approval from the Medical Equipment Committee of Clalit Health Services, enabling immediate procurement and deployment of the INSPIRA ART100 across Clalit's network serving approximately 4.9 million members.
The approval covers 14 major hospitals and over 1,600 clinics, follows a technical and clinical review by the relevant professional committee, and positions the ART100 for commercial use within one of the world’s largest integrated HMOs.